{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T05:03:26Z","timestamp":1761541406066,"version":"3.37.3"},"reference-count":32,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2017,11,23]],"date-time":"2017-11-23T00:00:00Z","timestamp":1511395200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Asia-Pac J Clncl Oncology"],"published-print":{"date-parts":[[2018,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Aim<\/jats:title><jats:p>External beam radiotherapy (EBRT) followed by high dose rate (HDR) brachytherapy boost has demonstrated minimal toxicities and improved disease control rate compared with EBRT alone in observational and randomized studies with predominantly Caucasian patients. This study aims to report the outcomes of patients treated with this approach in our predominantly Asian population.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Medical records for patients with localized prostate cancer who received combined EBRT delivered via intensity modulated radiotherapy (IMRT) technique followed by HDR brachytherapy boost were retrospectively reviewed. Outcomes evaluated included 5\u2010year biochemical recurrence\u2010free survival (per Phoenix definition), overall survival and treatment toxicities.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>From June 2009 to March 2015, 75 patients were treated with IMRT followed by HDR brachytherapy boost. Twenty patients (27%) had intermediate risk, 55 (74%) had high\u2010risk disease. Median follow up was 64 months. All patients received IMRT to a median dose of 45 Gy to the pelvis followed by HDR brachytherapy boost. Sixty, 10 and 5 patients received boost of 21 Gy in two fractions, 19 Gy in two fractions and 15 Gy in a single fraction, respectively. All patients met the planning criteria adapted from RTOG 0815. The 5\u2010year prostate\u2010specific antigen (PSA) control was 85.2% (80.3% and 100% for high\u2010risk and intermediate\u2010risk group, respectively). Cancer\u2010specific survival and overall survival are 97.3% and 92.0%, respectively. Eleven (15%) patients developed biochemical failure, six of which had distant metastasis. Three (4%) developed grade 3 genitourinary toxicity (urethral stricture and\/or cystitis) and none developed grade 3 radiation proctitis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Our outcomes are comparable to internationally published data and demonstrate reproducibility of this approach in our population.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ajco.12819","type":"journal-article","created":{"date-parts":[[2017,11,24]],"date-time":"2017-11-24T03:46:50Z","timestamp":1511495210000},"source":"Crossref","is-referenced-by-count":3,"title":["Outcomes of Asian patients with localized prostate cancer treated with combined intensity modulated radiation therapy (IMRT) and high dose rate (HDR) brachytherapy: A single institution experience"],"prefix":"10.1111","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8802-9654","authenticated-orcid":false,"given":"Ivy Wei Shan","family":"Ng","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology National Cancer Institute National University Hospital National University Health Systems, Singapore  Singapore"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeremy Chee Seong","family":"Tey","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology National Cancer Institute National University Hospital National University Health Systems, Singapore  Singapore"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu Yang","family":"Soon","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology National Cancer Institute National University Hospital National University Health Systems, Singapore  Singapore"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle Shu Fen","family":"Tseng","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology National Cancer Institute National University Hospital National University Health Systems, Singapore  Singapore"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Desiree","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology National Cancer Institute National University Hospital National University Health Systems, Singapore  Singapore"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keith Hsiu Chin","family":"Lim","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology National Cancer Institute National University Hospital National University Health Systems, Singapore  Singapore"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2017,11,23]]},"reference":[{"unstructured":"IARC Publications Website \u2010 World Cancer Report 2014 [Internet].Publications.iarc.fr.2014[cited 16 March 2017]. Available from:http:\/\/publications.iarc.fr\/Non-Series-Publications\/World-Cancer-Reports\/World-Cancer-Report-2014","key":"e_1_2_6_2_1"},{"unstructured":"Fact Sheets by Cancer [Internet].Globocan.iarc.fr.2012[cited 16 March 2017]. Available from:http:\/\/globocan.iarc.fr\/Pages\/fact_sheets_cancer.aspx","key":"e_1_2_6_3_1"},{"doi-asserted-by":"publisher","key":"e_1_2_6_4_1","DOI":"10.1038\/aja.2010.126"},{"doi-asserted-by":"publisher","key":"e_1_2_6_5_1","DOI":"10.1016\/S0360-3016(01)02664-5"},{"doi-asserted-by":"publisher","key":"e_1_2_6_6_1","DOI":"10.1016\/S0360-3016(01)01607-8"},{"doi-asserted-by":"publisher","key":"e_1_2_6_7_1","DOI":"10.1016\/j.brachy.2017.01.006"},{"doi-asserted-by":"publisher","key":"e_1_2_6_8_1","DOI":"10.1016\/j.radonc.2016.09.016"},{"doi-asserted-by":"publisher","key":"e_1_2_6_9_1","DOI":"10.1016\/j.ijrobp.2012.07.006"},{"doi-asserted-by":"publisher","key":"e_1_2_6_10_1","DOI":"10.1016\/j.radonc.2012.01.007"},{"doi-asserted-by":"publisher","key":"e_1_2_6_11_1","DOI":"10.1016\/j.ijrobp.2009.10.035"},{"doi-asserted-by":"publisher","key":"e_1_2_6_12_1","DOI":"10.1016\/j.brachy.2011.01.003"},{"doi-asserted-by":"publisher","key":"e_1_2_6_13_1","DOI":"10.1016\/j.ijrobp.2009.08.048"},{"doi-asserted-by":"publisher","key":"e_1_2_6_14_1","DOI":"10.1097\/COC.0b013e31818cd277"},{"doi-asserted-by":"publisher","key":"e_1_2_6_15_1","DOI":"10.1016\/j.urology.2007.03.008"},{"doi-asserted-by":"publisher","key":"e_1_2_6_16_1","DOI":"10.1016\/j.ijrobp.2004.08.014"},{"doi-asserted-by":"publisher","key":"e_1_2_6_17_1","DOI":"10.1016\/j.radonc.2004.10.014"},{"doi-asserted-by":"publisher","key":"e_1_2_6_18_1","DOI":"10.1016\/S0167-8140(98)00054-1"},{"doi-asserted-by":"publisher","key":"e_1_2_6_19_1","DOI":"10.1016\/S0022-5347(05)68365-6"},{"doi-asserted-by":"publisher","key":"e_1_2_6_20_1","DOI":"10.1001\/jama.280.11.969"},{"doi-asserted-by":"publisher","key":"e_1_2_6_21_1","DOI":"10.1016\/0360-3016(94)90138-4"},{"unstructured":"Prostate Pelvic Lymph Nodes [Internet].Rtog.org.2017[cited 16 March 2017]. Available from:https:\/\/www.rtog.org\/CoreLab\/ContouringAtlases\/ProstatePelvicLymphNodes.aspx","key":"e_1_2_6_22_1"},{"doi-asserted-by":"publisher","key":"e_1_2_6_23_1","DOI":"10.1120\/jacmp.v8i4.2415"},{"doi-asserted-by":"publisher","key":"e_1_2_6_24_1","DOI":"10.5114\/jcb.2014.45759"},{"doi-asserted-by":"publisher","key":"e_1_2_6_25_1","DOI":"10.1016\/j.radonc.2011.08.022"},{"doi-asserted-by":"publisher","key":"e_1_2_6_26_1","DOI":"10.1016\/j.brachy.2011.09.008"},{"doi-asserted-by":"publisher","key":"e_1_2_6_27_1","DOI":"10.1016\/j.radonc.2013.05.002"},{"unstructured":"RTOG | Clinical Trials | Study Number 0815 [Internet].Rtog.org.2015[cited 16 March 2017]. Available from:https:\/\/www.rtog.org\/ClinicalTrials\/ProtocolTable\/StudyDetails.aspx?study=0815","key":"e_1_2_6_28_1"},{"doi-asserted-by":"publisher","key":"e_1_2_6_29_1","DOI":"10.1016\/j.ijrobp.2006.04.029"},{"doi-asserted-by":"publisher","key":"e_1_2_6_30_1","DOI":"10.1200\/JCO.2009.25.8475"},{"doi-asserted-by":"publisher","key":"e_1_2_6_31_1","DOI":"10.1016\/j.ijrobp.2007.06.054"},{"unstructured":"Prostate Cancer | Uroweb [Internet].Uroweb.2015[cited 16 March 2017]. Available from:http:\/\/uroweb.org\/guideline\/prostate-cancer\/","key":"e_1_2_6_32_1"},{"doi-asserted-by":"publisher","key":"e_1_2_6_33_1","DOI":"10.1016\/j.clon.2014.10.006"}],"container-title":["Asia-Pacific Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fajco.12819","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ajco.12819","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,17]],"date-time":"2023-09-17T23:25:10Z","timestamp":1694993110000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ajco.12819"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,23]]},"references-count":32,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["10.1111\/ajco.12819"],"URL":"https:\/\/doi.org\/10.1111\/ajco.12819","archive":["Portico"],"relation":{},"ISSN":["1743-7555","1743-7563"],"issn-type":[{"type":"print","value":"1743-7555"},{"type":"electronic","value":"1743-7563"}],"subject":[],"published":{"date-parts":[[2017,11,23]]}}}